for the Period Ended 31 March 2025
| Directors report | |
| Profit and loss | |
| Balance sheet | |
| Additional notes | |
| Balance sheet notes | |
| Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 March 2025
Principal activities of the company
Additional information
The objects of the company are to carry on activities that benefit the community and in particular (without limitation): To provide an administrative framework supporting the activities of External Quality Assessment (EQA) in cancer diagnostic testing in clinical laboratory sciences. It will operate on a not-for-profit basis; conform to high professional standards; act impartially; be strictly financially accountable. In order that all concerned with the quality of laboratory investigations may have confidence in the services provided, it will assess the quality of clinical laboratory testing in the areas of cancer diagnosis and prediction of treatment response. This testing is carried out in laboratories throughout the UK and worldwide, and by providing external quality assessments, the company will assist healthcare professionals to assure the quality of the work undertaken in their laboratories, which in turn will help to facilitate optimal care for cancer patients undergoing treatment for their disease in the UK and across the world.
Directors
The directors shown below have held office during the whole of the period from
1 April 2024
to
31 March 2025
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
| 2025 | 2024 | |
|---|---|---|
|
|
£ |
£ |
| Turnover: |
|
|
| Cost of sales: |
(
|
(
|
| Gross profit(or loss): |
|
|
| Administrative expenses: |
(
|
(
|
| Operating profit(or loss): |
( |
( |
| Interest receivable and similar income: |
|
|
| Interest payable and similar charges: |
(
|
|
| Profit(or loss) before tax: |
( |
( |
| Tax: |
|
|
| Profit(or loss) for the financial year: |
( |
|
As at
| Notes | 2025 | 2024 | |
|---|---|---|---|
|
|
£ |
£ |
|
| Fixed assets | |||
| Intangible assets: | 3 |
|
|
| Tangible assets: | 4 |
|
|
| Total fixed assets: |
|
|
|
| Current assets | |||
| Stocks: | 5 |
|
|
| Debtors: | 6 |
|
|
| Cash at bank and in hand: |
|
|
|
| Total current assets: |
|
|
|
| Creditors: amounts falling due within one year: | 7 |
(
|
(
|
| Net current assets (liabilities): |
|
|
|
| Total assets less current liabilities: |
|
|
|
| Provision for liabilities: |
(
|
(
|
|
| Total net assets (liabilities): |
|
|
|
| Members' funds | |||
| Profit and loss account: |
|
|
|
| Total members' funds: |
|
|
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 March 2025
Basis of measurement and preparation
Turnover policy
Tangible fixed assets depreciation policy
Intangible fixed assets amortisation policy
for the Period Ended 31 March 2025
| 2025 | 2024 | |
|---|---|---|
| Average number of employees during the period |
|
|
for the Period Ended 31 March 2025
| Goodwill | Other | Total | |
|---|---|---|---|
| Cost | £ | £ | £ |
| At 1 April 2024 |
|
|
|
| Additions |
|
|
|
| Disposals | |||
| Revaluations | |||
| Transfers | |||
| At 31 March 2025 |
|
|
|
| Amortisation | |||
| At 1 April 2024 |
|
|
|
| Charge for year |
|
|
|
| On disposals | |||
| Other adjustments | |||
| At 31 March 2025 |
|
|
|
| Net book value | |||
| At 31 March 2025 |
|
|
|
| At 31 March 2024 |
|
|
for the Period Ended 31 March 2025
| Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
|---|---|---|---|---|---|---|
| Cost | £ | £ | £ | £ | £ | £ |
| At 1 April 2024 |
|
|
|
|||
| Additions |
|
|
|
|||
| Disposals | ||||||
| Revaluations | ||||||
| Transfers | ||||||
| At 31 March 2025 |
|
|
|
|||
| Depreciation | ||||||
| At 1 April 2024 |
|
|
|
|||
| Charge for year |
|
|
|
|||
| On disposals | ||||||
| Other adjustments | ||||||
| At 31 March 2025 |
|
|
|
|||
| Net book value | ||||||
| At 31 March 2025 |
|
|
|
|||
| At 31 March 2024 |
|
|
|
for the Period Ended 31 March 2025
| 2025 | 2024 | |
|---|---|---|
| £ | £ | |
| Stocks |
|
|
| Total |
|
|
for the Period Ended 31 March 2025
| 2025 | 2024 | |
|---|---|---|
| £ | £ | |
| Trade debtors |
|
|
| Prepayments and accrued income |
|
|
| Other debtors |
|
|
| Total |
|
|
for the Period Ended 31 March 2025
| 2025 | 2024 | |
|---|---|---|
| £ | £ | |
| Trade creditors |
|
|
| Taxation and social security |
|
|
| Accruals and deferred income |
|
|
| Other creditors |
|
|
| Total |
|
|
The Company has supported the activities of a UK-based external quality assessment (EQA) scheme, which provides its services to healthcare laboratories throughout the world. Currently the number of laboratories receiving EQA services is in excess of 500, with approximately 40% of them being based in the UK. By providing these EQA services the Company through its Scheme allows laboratories to benchmark the quality of their clinical testing activities against those of its peers, providing assurance that the quality of testing is good in the vast majority of cases. Where deficiencies in test quality are identified the Scheme works with the laboratory to improve that quality, through the provision of education and advice.
There has been consultation with all stakeholder groups. 1.Clinical laboratories participating in the EQA activities are provided with an annual questionnaire designed to obtain their feedback about all aspects of the EQA services. The company provides an outward-facing website, through which participants may contact the EQA Scheme. 2.The EQA Scheme is part of a wider consortium of similar operations hosted by various legal entities (mainly NHS teaching hospitals). Directors from EQASCD CIC regularly attend joint meetings of that consortium group (up to 7 meetings per year).
The total amount paid or receivable by directors in respect of qualifying services was £248,632. There were no other transactions or arrangements in connection with the remuneration of directors which require to be disclosed.
No transfer of assets other than for full consideration
This report was approved by the board of directors on
24 December 2025
And signed on behalf of the board by:
Name: A R Dodson
Status: Director